SGLT2 inhibitor
Ertugliflozin
Brand names: Steglatro
Adult dose
Dose: 5mg OD (max 15mg OD)
Route: Oral
Frequency: OD
Clinical pearls
- NICE NG28: SGLT2i class option; empagliflozin and dapagliflozin have stronger CV/renal outcome evidence
- ADA-EASD and ESC HF: SGLT2i for HF and CKD reduction
- MHRA DKA / volume depletion warnings
Contraindications
- Type 1 diabetes
- DKA history
- Severe renal impairment
- Pregnancy
- Hypersensitivity
Side effects
- Genitourinary infections
- Volume depletion
- DKA (atypical)
- Fournier's gangrene
- Lower-limb amputation signal (less robust than canagliflozin)
Interactions
- Diuretics
- RAAS inhibitors
- Insulin/sulfonylureas (hypoglycaemia)
Monitoring
- HbA1c
- eGFR
- Volume status
- Foot care
- Sick-day rules
Reference: BNF; NICE NG28; MHRA Drug Safety Update; ADA-EASD consensus; https://bnf.nice.org.uk/drugs/ertugliflozin/. Verify against your local formulary and the latest BNF before prescribing.
Related
Curated clinical cross-links plus same-class fallbacks.
Calculators
- SCORE2-Diabetes 10-Year CVD Risk in Type 2 Diabetes · Cardiovascular Risk
- PCP-HF Risk Score (Pooled Cohort Equations to Prevent Heart Failure) · Heart Failure Prevention
- SMART Risk Score for Recurrent CVD · Cardiovascular Risk
- PCSK9 Inhibitor Eligibility Assessment · Lipid Management
- Immune-Related Adverse Events (irAE) -- GI Toxicity Colitis Grading · Oncology-Related GI
- irAE Hepatitis Grading (CTCAE) · Immunotherapy
Drugs
Pathways
- Diabetic Ketoacidosis (DKA) · JBDS 2013 / Joint British Diabetes Societies; NICE NG17
- Adult Hypoglycaemia (Treated Diabetes) · JBDS-IP (2023): Hospital Management of Hypoglycaemia
- Adrenal Crisis · Society for Endocrinology Emergency Guidance (2024)
- Type 2 Diabetes Management · NICE NG28 2022
- Hyperthyroidism Management · BTA / ETA 2018
- Adrenal Insufficiency · Society of Endocrinology / ESE 2016